FERDINANDOS SKOULIDIS to Precision Medicine
This is a "connection" page, showing publications FERDINANDOS SKOULIDIS has written about Precision Medicine.
Connection Strength
0.102
-
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor. Clin Cancer Res. 2016 Nov 01; 22(21):5177-5182.
Score: 0.078
-
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 2020 Jan 31; 20(1):83.
Score: 0.025